Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret them. Tarsus is a commercial-stage biopharmaceutical company focused on therapeutics starting with eye care, led by XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis and a lotilaner-based pipeline that includes TP-04 and TP-05.
Through this page, users can access Tarsus’ current and historical filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s business, risk factors, financial statements, and discussion of results. Current reports on Form 8-K provide details on material events such as quarterly financial results, annual meeting outcomes, and other significant corporate developments. For example, recent 8-K filings reference press releases that set forth Tarsus’ results of operations for specific quarters and describe shareholder voting results at the annual meeting.
Investors can also review proxy statements referenced in 8-K filings to understand proposals submitted to stockholders, including director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. In addition, Form 4 insider transaction reports, when available, can be used to track purchases and sales of TARS shares by directors, officers, and other insiders.
Stock Titan’s AI features summarize lengthy filings, highlight key sections related to revenue dependence on XDEMVY, pipeline development, capital needs, and risk factors, and explain technical language in more accessible terms. Real-time updates from EDGAR ensure that new Tarsus filings, from 10-K and 10-Q reports to 8-K current reports and Form 4 insider filings, appear promptly so users can follow changes in the company’s regulatory and financial profile without manually parsing every document.
Prudential Financial, Inc. filed an Amendment No. 20 on Schedule 13G/A reporting beneficial ownership of 1,836,321 shares of Common Stock of Tarsus Pharmaceuticals, Inc. (4.3%) as of 03/31/2026. The filing shows shared voting power of 1,670,648 and shared dispositive power of 1,836,321. The disclosure attributes holdings to subsidiaries, including Jennison Associates LLC: 1,712,124 shares (4.0%), The Prudential Insurance Company of America: 117,972 shares (0.3%), and PGIM Quantitative Solutions LLC: 6,225 shares.
TARSUS PHARMACEUTICALS INC Schedule 13G/A amendment reports that Jennison Associates LLC beneficially owns 1,712,124 shares of common stock, representing 4.0% of the class. The filing lists sole voting power for 1,712,124 shares and shared dispositive power for 1,712,124 shares.
Tarsus Pharmaceuticals reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Total revenue reached $162.1 million, driven by $145.4 million in XDEMVY product sales and $16.7 million of license and collaboration revenue.
Operating expenses rose to $168.2 million, mainly from higher selling, general and administrative and R&D spending. Net loss narrowed to $7.0 million, or $0.16 per share, compared with a $25.1 million loss a year earlier. Cash, cash equivalents and marketable securities totaled over $388 million, and management believes existing capital will fund operations for at least 12 months, though additional financing may still be needed as the company scales commercialization and advances its pipeline.
Tarsus Pharmaceuticals reported strong first quarter 2026 growth driven by XDEMVY. Net product sales were $145.4 million, more than 85% higher than a year earlier, and total revenue reached about $162.1 million including $16.7 million of license and collaboration revenue from a China milestone.
The company reaffirmed full-year 2026 XDEMVY net product sales guidance of $670–700 million and continues to highlight peak sales potential exceeding $2 billion. Operating expenses rose as Tarsus invested heavily in commercialization and R&D, yet net loss narrowed to $7.0 million, or $(0.16) per share.
Cash, cash equivalents and marketable securities totaled $388.7 million as of March 31, 2026, supporting a pipeline that includes Phase 2 programs for ocular rosacea (TP-04) and Lyme disease prevention (TP-05), with topline data from both expected in the first half of 2027.
Tarsus Pharmaceuticals, Inc. director David E. I. Pyott acquired common stock through equity compensation rather than open‑market trading. On April 24, 2026, 1,383 shares of common stock were issued upon settlement of vested Restricted Stock Units (RSUs), with each RSU converting into one share.
The RSUs vested in full on that date, subject to his continuous service. Following these transactions, he holds 1,383 shares directly and 7,991 shares indirectly through the David E.I. Pyott Trust.
Tarsus Pharmaceuticals, Inc. filed its Form 10-K for the fiscal year ended December 31, 2025 describing its commercial launch and continued development programs.
The company reported net product sales of $451.4M for 2025 and delivered approximately 400,000 bottles during the year; launch-to-date net product sales are reported at $646M. The company notes an aggregate market value of common equity held by non-affiliates of approximately $1.7B as of June 30, 2025, and 42,557,492 shares outstanding as of February 17, 2026.
The report summarizes commercialization progress for XDEMVY (lotilaner ophthalmic solution) 0.25% (FDA approved July 2023, launched August 2023), ongoing clinical programs for TP-04 (ocular rosacea) and TP-05 (Lyme disease prophylaxis), license arrangements with Elanco and GrandPharma, manufacturing reliance on CMOs, and key risks including continued losses, supply dependencies, and reimbursement and market adoption uncertainties.
Tarsus Pharmaceuticals, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 25, 2026. Investors will elect four Class III directors to serve until 2029, cast an advisory vote on executive compensation, and ratify Ernst & Young LLP as independent auditor for 2026.
The proxy explains how to attend and vote online and confirms 43,023,959 common shares were outstanding on April 27, 2026. It also outlines board structure, committee memberships, director pay, and a pay-for-performance program for executives, including cash bonuses funded at 108% of target and expanded use of stock options, RSUs, and new performance-based RSUs.
The Vanguard Group filed an Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned of Tarsus Pharmaceuticals Inc common stock and 0% of the class. The filing explains an internal realignment that caused certain subsidiaries to report ownership separately and is signed on 03/27/2026.
Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan sold 2,989 shares of common stock in an open-market transaction at $66.75 per share on March 20, 2026. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the sale, he holds 82,791 shares directly. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those shares.
Seshadri Neervannan reported proposed and completed sales of Common Stock of TARS. The filing lists restricted shares vesting on 03/16/2026 (1,093 shares), 03/17/2026 (1,087 shares) and 03/18/2026 (809 shares). The filing also reports open-market sales during the prior three months of 8,366, 3,125, 3,610 and 4,589 shares on 03/04/2026, 03/17/2026, 03/18/2026 and 03/19/2026, respectively, with aggregate proceeds shown per sale.